New drug brazikumab aims to tame ulcerative colitis Flare-Ups

NCT ID NCT03616821

Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This phase 2 trial tested brazikumab in 242 adults with moderate-to-severe ulcerative colitis. Participants received either brazikumab or a placebo intravenously and then as injections over 54 weeks. The goal was to see if the drug could improve symptoms and heal the colon lining. The study was terminated early, so final conclusions are limited.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance: brazikumab
What this could lead to: If successful, brazikumab could offer a new treatment option to control moderate-to-severe ulcerative colitis and improve symptoms and colon healing.
What could go wrong: This is an early-phase trial that was terminated, so results are limited. The drug may not work better than placebo, and side effects are still being studied.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Phase 2

Tests whether the treatment actually works, and watches for side effects, in a larger group.

Participants

242 people

The number who actually took part.

Started

Aug 2018

Finished

Oct 2023

Lead sponsor

A company

The lead sponsor is a pharmaceutical, biotech, or medical-device company.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 to 80 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Ability to provide informed consent 2. Aged 18 to 80 years of age 3. Diagnosis of UC with an onset of symptoms for a minimum of 3 months prior to Screening 4. Evidence of UC extending proximal to the rectum (≥ 15 cm of involved colon) 5. Moderately to severely active UC as defined by: 1. Average daily mMS Stool Frequency subscore ≥ 1 AND Average daily mMS Rectal Bleeding subscore ≥ 1 2. Modified Mayo endoscopic subscore of ≥ 2 based on a full colonoscopy within 14 days prior to randomization. 6. Participant had an inadequate response or intolerance to intervention with conventional treatment or prior biological treatment or demonstrated CS dependence for the treatment of UC. For participants who have previously used biological treatment, a participant may have failed up to 3 biologics that include up to 2 different mechanisms of action. 7. Participants taking 5-aminosalicylates, oral prednisone (or equivalent), oral budesonide, or immunomodulators must be at a stable dose or discontinued. Topical (rectal) aminosalicylic acid or topical (rectal) steroids should be discontinued. 8. Female participants of childbearing potential must have a negative urine pregnancy test prior to administration of study intervention and must agree to use a highly effective method of birth control throughout the study and for at least 18 weeks after the last dose of study intervention. 9. Women not of childbearing potential are defined as women who are either permanently sterilized (hysterectomy, bilateral oophorectomy, or bilateral salpingectomy), or who are postmenopausal. 10. Non sterilized males who are sexually active with a female partner of childbearing potential should use condoms during treatment and until the end of relevant systemic exposure in the male participant, plus a further 18 weeks. 11. No known history of active TB or latent TB without completion of appropriate intervention and negative QFT-TB during Screening. Complete inclusion criteria are in the Clinical Study Protocol Exclusion Criteria: 1. Participant has UC limited to the rectum (ie, not beyond 15 cm of the anal verge). 2. Current diagnosis of fulminant colitis, a diagnosis of CD or indeterminate colitis, presence or history of a fistula consistent with CD, primary sclerosing cholangitis, celiac disease, or untreated bile acid malabsorption. Participants with a history of toxic megacolon within 12 months of screening are excluded. 3. History of subtotal colectomy with ileorectostomy or colectomy with ileoanal pouch, Koch pouch, ileostomy, or other prior colonic resection, or need for surgical intervention for control of UC anticipated within 6 months. 4. Participant has received the following treatment: 1. Infliximab: within 8 weeks prior to randomization. 2. Adalimumab, certolizumab pegol, or golimumab: within 8 weeks prior to randomization. 3. Vedolizumab or ustekinumab within 12 weeks of randomization. 4. Other prohibited medication, biologic or small molecule treatment within 5 half-lives prior to randomization. 5. Fecal microbiota transplantation: within 8 weeks prior to randomization. 5. Criterion deleted as part of Amendment 5 v6.0 6. Except for ustekinumab, prior exposure to any biologic agent targeting IL-12 or IL-23. 7. Known history of allergy to the study intervention formulation or any of its excipients or components of the delivery device, or to any other biologic therapy. 8. Participant received cyclosporine, mycophenolate mofetil, sirolimus (rapamycin), thalidomide, tacrolimus (FK-506), or tofacitinib within 2 weeks prior to Screening. 9. Participants who received IV or intramuscular steroids within 2 weeks prior to Screening. 10. Participant is currently enrolled in another investigational device or drug study, or is within 35 days or 5 half-lives, whichever is longer, since ending another investigational device or drug study(s), or receiving other investigational agent(s). 11. Participant received a transfusion of blood, plasma, or platelets within 30 days prior to Screening. 12. Participant received a Bacille Calmette-Guérin vaccination within 12 months of randomization or any other live vaccine less than 4 weeks prior to randomization. 13. Participant has any of the following criteria related to infections: 1. Evidence of a recent systemic fungal infection, requiring inpatient hospitalization, and/or antifungal treatment. 2. Any infection requiring hospitalization or treatment with IV anti-infectives within 4 weeks of Screening. 3. Cytomegalovirus or Epstein-Barr virus infection that has not resolved within 8 weeks prior to Screening. 4. Clinically significant chronic infection that has not resolved within 8 weeks of Screening. 5. Nonserious infection requiring oral anti-infectives within 2 weeks prior to randomization must be further discussed with study medical monitor. 6. Clinical evidence of or suspected to have an abscess during Screening. 7. Any underlying condition that predisposes the participant to infections. 8. Participant had previous allogenic bone marrow transplant or history of organ or cell-based transplantation. 9. Clinically significant active infection or signs/symptoms of infection that has the potential to worsen with immunosuppressive therapy. 10. Signs or symptoms of ongoing infection due to intestinal pathogens. 14. Participant has known or suspected history of chronic use of NSAIDs and/or opiates, drug, or alcohol abuse. 15. History of cancer with the following exceptions: history of basal cell carcinoma and/or squamous cell carcinoma of the skin OR carcinoma in situ of the cervix; with apparent successful curative therapy, greater than 12 months prior to Screening. 16. Clinically significant cardiovascular conditions. 17. Prolonged QTcF interval or conditions leading to additional risk for QT prolongation. 18. Clinically significant kidney disease 19. Abnormal laboratory results at Screening as defined in the study protocol 20. Participant is pregnant or breastfeeding or plans to become pregnant during the study. 21. Participant has other known, pre-existing, clinically significant medical conditions that are not associated with UC and are uncontrolled with standard treatment. 22. Participant has any disorder that may compromise the ability of the participant to give written informed consent and/or to comply with all required study procedures. 23. Employees of the clinical study site or any other individuals involved with the conduct of the study, or immediate family members of such individuals. Complete exclusion criteria are in the Clinical Study Protocol

Get updates

Get notified about this study

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

inflammatory bowel disease ulcerative colitis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

IBD Ulcerative colitis

Contacts and locations

Locations

Research Site

Phoenix, Arizona, 85037, United States
Research Site

Tucson, Arizona, 85712, United States
Research Site

Little Rock, Arkansas, 72212, United States
Research Site

Chula Vista, California, 91911, United States
Research Site

Lancaster, California, 93534, United States
Research Site

Lincoln, California, 95648, United States
Research Site

Mission Hills, California, 91345, United States
Research Site

Poway, California, 92064, United States
Research Site

Colorado Springs, Colorado, 80907, United States
Research Site

Clearwater, Florida, 33756, United States
Research Site

Inverness, Florida, 34452, United States
Research Site

Kissimmee, Florida, 34741, United States
Research Site

Lakeland, Florida, 33813, United States
Research Site

Miami, Florida, 33157, United States
Research Site

Miami, Florida, 33165, United States
Research Site

Miami Lakes, Florida, 33016, United States
Research Site

Naples, Florida, 34102, United States
Research Site

New Port Richey, Florida, 34653, United States
Research Site

Tampa, Florida, 33614, United States
Research Site

Tampa, Florida, 33626, United States
Research Site

Atlanta, Georgia, 30328, United States
Research Site

Gurnee, Illinois, 60031, United States
Research Site

Oak Lawn, Illinois, 60453, United States
Research Site

Brownsburg, Indiana, 46112, United States
Research Site

Evansville, Indiana, 47715, United States
Research Site

Shawnee Mission, Kansas, 66226, United States
Research Site

Topeka, Kansas, 66606, United States
Research Site

Baton Rouge, Louisiana, 70809, United States
Research Site

Marrero, Louisiana, 70072, United States
Research Site

Shreveport, Louisiana, 71105, United States
Research Site

Wyoming, Michigan, 49519, United States
Research Site

Biloxi, Mississippi, 39531, United States
Research Site

Las Vegas, Nevada, 89106, United States
Research Site

Las Vegas, Nevada, 89123, United States
Research Site

New York, New York, 10016, United States
Research Site

Sunnyside, New York, 11104, United States
Research Site

Morehead City, North Carolina, 28557, United States
Research Site

Beachwood, Ohio, 44122, United States
Research Site

Springfield, Ohio, 45503, United States
Research Site

Oklahoma City, Oklahoma, 73112, United States
Research Site

Uniontown, Pennsylvania, 15401, United States
Research Site

Amarillo, Texas, 79109, United States
Research Site

Carrollton, Texas, 75007, United States
Research Site

Houston, Texas, 77017, United States
Research Site

Houston, Texas, 77058, United States
Research Site

Houston, Texas, 77598, United States
Research Site

Humble, Texas, 77346, United States
Research Site

Pflugerville, Texas, 78660, United States
Research Site

San Antonio, Texas, 78229, United States
Research Site

San Antonio, Texas, 78258, United States
Research Site

North Chesterfield, Virginia, 23236, United States
Research Site

Chicoutimi, Quebec, G7H 5H6, Canada
Research Site

Brno, 636 00, Czechia
Research Site

České Budějovice, 370 01, Czechia
Research Site

Hradec Králové, 500 12, Czechia
Research Site

Ostrava, 702 00, Czechia
Research Site

Hamburg, 20251, Germany
Research Site

Kiel, 24105, Germany
Research Site

Ulm, 89081, Germany
Research Site

Debrecen, 4032, Hungary
Research Site

Bangalore, 560054, India
Research Site

Hyderabad, 500032, India
Research Site

Jaipur, 302001, India
Research Site

New Delhi, 110075, India
Research Site

Rajkot, 360004, India
Research Site

Surat, 395002, India
Research Site

Haifa, 31096, Israel
Research Site

Jerusalem, 9103102, Israel
Research Site

Petah Tikva, 4941492, Israel
Research Site

Milan, 20132, Italy
Research Site

Negrar, 37024, Italy
Research Site

Rho, 20017, Italy
Research Site

Roma, 00168, Italy
Research Site

Asahikawa-shi, 070-8610, Japan
Research Site

Chiba, 260-8677, Japan
Research Site

Fukuoka, 810-8563, Japan
Research Site

Fukuyama-shi, Japan
Research Site

Hakodate-shi, 040-8585, Japan
Research Site

Kasama-shi, 309-1793, Japan
Research Site

Kashiwa-shi, 277-0871, Japan
Research Site

Koshigaya-shi, 343-8555, Japan
Research Site

Kure-shi, 737-0023, Japan
Research Site

Minatoku, 108-8642, Japan
Research Site

Nagaoka-shi, 940-2085, Japan
Research Site

Onga-gun, 807-0051, Japan
Research Site

Sapporo, 064-0919, Japan
Research Site

Takarazuka-shi, 665-0827, Japan
Research Site

Bydgoszcz, 85-079, Poland
Research Site

Chojnice, 89-600, Poland
Research Site

Częstochowa, 42-202, Poland
Research Site

Gdansk, 80-382, Poland
Research Site

Krakow, 31-513, Poland
Research Site

Ksawerów, 95-054, Poland
Research Site

Piaseczno, 05-500, Poland
Research Site

Poznan, 60-702, Poland
Research Site

Rzeszów, 35-302, Poland
Research Site

Sopot, 81-756, Poland
Research Site

Torun, 87-100, Poland
Research Site

Warsaw, 00-189, Poland
Research Site

Warsaw, 03-580, Poland
Research Site

Wroclaw, 52-210, Poland
Research Site

San Juan, 00927, Puerto Rico
Research Site

Aramil, 624002, Russia
Research Site

Izhevsk, 426035, Russia
Research Site

Moscow, 115419, Russia
Research Site

Novosibirsk, 630007, Russia
Research Site

Perm, 614000, Russia
Research Site

Tomsk, 634050, Russia
Research Site

Košice, 04013, Slovakia
Research Site

Bloemfontein, 9301, South Africa
Research Site

Cape Town, 7500, South Africa
Research Site

Cape Town, 7708, South Africa
Research Site

Plumstead, 7800, South Africa
Research Site

Busan, 48108, South Korea
Research Site

Daegu, 42415, South Korea
Research Site

Seoul, 03722, South Korea
Research Site

Seoul, 06351, South Korea
Research Site

Seoul, 06973, South Korea
Research Site

Wŏnju, 26426, South Korea
Research Site

Valencia, 46010, Spain
Research Site

Taichung, 40447, Taiwan
Research Site

Taipei, 100, Taiwan
Research Site

Kyiv, 03680, Ukraine
Research Site

Vinnytsia, 21009, Ukraine
Research Site

West Bromwich, B71 4HJ, United Kingdom

More trials for these conditions

Other studies related to the condition(s) this trial covers.